HLA-DQA105 Was Not Associated With Primary Nonresponse or Loss of Response to First Anti-TNF in Real-World Inflammatory Bowel Disease Patients

• Published in: Inflammatory bowel diseases Vol. 30; no. 6; p. 922
• Main Authors: Pascual-Oliver, Andrea, Casas-Deza, Diego, Cuarán, Camila, García-López, Santiago, Corsino-Roche, Pilar, Sierra-Moros, Eva, Olier-Martínez, Pilar, González-Tarancón, Ricardo, Vicente-Lidón, Raquel
• Format: Journal Article
• Language: English
• Published: England 03-06-2024
• Subjects: Adult; Colitis, Ulcerative - drug therapy; Colitis, Ulcerative - genetics; Crohn Disease - drug therapy; Crohn Disease - genetics; Female; Follow-Up Studies; HLA-DQ alpha-Chains - genetics; Humans; Inflammatory Bowel Diseases - drug therapy; Inflammatory Bowel Diseases - genetics; Infliximab - therapeutic use; Male; Middle Aged; Retrospective Studies; Treatment Failure; Tumor Necrosis Factor-alpha - antagonists & inhibitors; Young Adult; HLA-DQA105; loss of response; safety; inflammatory bowel disease; anti-TNF
• ISSN: 1078-0998; 1536-4844; 1536-4844
• DOI: 10.1093/ibd/izad130

We lack predictors of response to biologics in the management of patients with inflammatory bowel disease (IBD). A recent study has shown a significant association between HLA-DQA1*05 carriers and the development of loss of response to anti-tumor necrosis factor (TNF) mediated by immunogenicity.
Retrospective single-center cohort study including IBD patients who had received anti-TNF therapy as a first biologic and whose HLA-DQA1*05 had been determined. Primary nonresponse and secondary failure (assessed by survival analysis) have been evaluated as well as safety outcomes.
A total of 199 IBD patients (161 [81%] with Crohn's disease and 38 [19%] with ulcerative colitis) were included. A total of 42.4% were HLA-DQA1*05 carriers and 60% received combination therapy at the start of anti-TNF treatment. Median follow-up was 24 (interquartile range, 11-66) months. No statistically significant differences were found in primary nonresponse to anti-TNF (89.3% vs 87.8%; P = .825), depending on HLA carriers and noncarriers. No differences in secondary loss of response according to HLA variant in any of the analyses performed (full cohort, according to IBD or anti-TNF type) were observed. Again, no differences were observed in patients treated with combination therapy. In terms of safety, no significant differences were found in the rate of infusion reactions or serious adverse events.
In our real-life cohort of IBD patients treated for the first time with anti-TNF, being an HLA-DQA1*05 carrier did not act as a predictor of response failure, either primary or secondary. The safety of anti-TNF treatment has also not been influenced by the variant.